Arbutus Biopharma Corporation (ABUS)
NASDAQ:ABUS

Arbutus Biopharma (ABUS) Stock Price & Analysis

1,106 Followers

ABUS Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.85 - $3.15
Previous Close$2.5
Volume453.32K
Average Volume (3M)861.53K
Market Cap
$415.33M
Enterprise Value$270.72M
Total Cash (Recent Filing)$146.73M
Total Debt (Recent Filing)$2.12M
Price to Earnings (P/E)-5.5
Beta0.56
Aug 03, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding166,133,563
10 Day Avg. Volume531,768
30 Day Avg. Volume861,534
Standard Deviation0.29
R-Squared0.17
Alpha0.00538
Financial Highlights & Ratios
Price to Book (P/B)2.91
Price to Sales (P/S)75.39
Price to Cash Flow (P/CF)-3.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.47
Enterprise Value/Gross Profit6.94
Enterprise Value/Ebitda-3.89
Forecast
Price Target Upside113.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4


Financials

Annual

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

ABUS FAQ

What was Arbutus Biopharma Corporation’s price range in the past 12 months?
Arbutus Biopharma Corporation lowest stock price was $1.85 and its highest was $3.15 in the past 12 months.
    What is Arbutus Biopharma Corporation’s market cap?
    Currently, no data Available
    When is Arbutus Biopharma Corporation’s upcoming earnings report date?
    Arbutus Biopharma Corporation’s upcoming earnings report date is Aug 03, 2023 which is in 66 days.
      How were Arbutus Biopharma Corporation’s earnings last quarter?
      Arbutus Biopharma Corporation released its earnings results on May 04, 2023. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.136 by $0.036.
        Is Arbutus Biopharma Corporation overvalued?
        According to Wall Street analysts Arbutus Biopharma Corporation’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Arbutus Biopharma Corporation pay dividends?
          Arbutus Biopharma Corporation does not currently pay dividends.
          What is Arbutus Biopharma Corporation’s EPS estimate?
          Arbutus Biopharma Corporation’s EPS estimate is -$0.11.
            How many shares outstanding does Arbutus Biopharma Corporation have?
            Arbutus Biopharma Corporation has 166,133,560 shares outstanding.
              What happened to Arbutus Biopharma Corporation’s price movement after its last earnings report?
              Arbutus Biopharma Corporation reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.136. Following the earnings report the stock price went up 1.594%.
                Which hedge fund is a major shareholder of Arbutus Biopharma Corporation?
                Among the largest hedge funds holding Arbutus Biopharma Corporation’s share is Woodline Partners LP. It holds Arbutus Biopharma Corporation’s shares valued at 8M.

                  ---

                  Arbutus Biopharma Stock Smart Score

                  The Arbutus Biopharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Arbutus Biopharma Corporation

                  Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company is headquartered in Burnaby, Canada.

                  ---

                  Top 5 ETFs holding ABUS

                  Name
                  Market Value
                  Smart Score
                  iShares Core S&P Total U.S. Stock Market ETF
                  $284.96K
                  8
                  iShares NASDAQ US Biotechnology UCITS ETF
                  $182.72K
                  8
                  iShares Russell 3000 ETF
                  $119.82K
                  8
                  Invesco Nasdaq Biotechnology ETF
                  $7.67K
                  8
                  Up to five ETFs with an Outperform Smart Score that hold ABUS. The ETFs are listed according to market value of ABUS within the ETF

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Nkarta
                  Scholar Rock Holding
                  C4 Therapeutics
                  Lexicon Pharmaceuticals
                  Poseida Therapeutics

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis